Trial Profile
Denosumab Counteracts Metabolic Bone Disease in Chronic Intestinal Failure Patients: A Randomized, Controlled Clinical Trial
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 05 Aug 2016
Price :
$35
*
At a glance
- Drugs Denosumab (Primary)
- Indications Metabolic bone diseases
- Focus Therapeutic Use
- Acronyms Denoz
- 05 Aug 2016 New trial record